openPR Logo
Press release

Radiopharmaceutical Theranostics Market Size is Expected to expand at a CAGR of 15.1% by 2031 |Transparency Market Research

03-19-2024 09:14 AM CET | Health & Medicine

Press release from: Transparency Market Research

Radiopharmaceutical Theranostics Market Size is Expected

The Radiopharmaceutical Theranostics Market involves the use of radiopharmaceuticals for both diagnostic imaging (diagnostics) and targeted therapy (therapeutics) in the management of various diseases, including cancer, neuroendocrine tumors, and cardiovascular conditions. Theranostics refers to the integration of diagnostic and therapeutic modalities, allowing for personalized medicine approaches tailored to individual patient characteristics. Radiopharmaceuticals, which emit radiation for imaging or therapeutic purposes, play a crucial role in diagnosing, staging, and treating diseases at the molecular level.

Radiopharmaceutical Theranostics market is estimated to attain a valuation of US$ 12.4 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 15.1% during the forecast period, 2023-2031

Get a Sample Copy of the Radiopharmaceutical Theranostics Market Research Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82604&utm_source=openpr_amitugare&utm_medium=openpr

The significant players operating in the global Radiopharmaceutical Theranostics market are

Advanced Accelerator Applications (Novartis AG), Aurobindo Pharma, Bayer AG, Blue Earth Diagnostics (Bracco), Cardinal Health, Clarity Pharmaceuticals, GE Healthcare, Jubliant Radiopharma, Navidea Biopharmaceuticals, Inc., SOFIE, Telix Pharmeceuticals, and Lantheus Medical Imaging

Key Drivers of the Radiopharmaceutical Theranostics Market:

Growing Incidence of Cancer: The increasing incidence of cancer globally, along with the demand for more effective and personalized treatment options, drives the adoption of radiopharmaceutical theranostics. Targeted radionuclide therapies offer the potential to selectively deliver radiation to cancer cells while sparing healthy tissues, leading to improved therapeutic outcomes and reduced side effects.

Advancements in Molecular Imaging: Technological advancements in molecular imaging techniques, such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and hybrid imaging modalities (PET/CT, PET/MRI), enable precise localization and characterization of tumors. Radiopharmaceutical-based imaging agents facilitate early detection, accurate staging, and treatment planning in oncology and other disease areas.

Personalized Medicine Approaches: The shift towards personalized medicine approaches, including molecular profiling, genetic testing, and companion diagnostics, drives the demand for targeted therapies and theranostic agents. Radiopharmaceutical theranostics allows for individualized treatment strategies based on tumor biology, receptor expression patterns, and patient-specific factors.

Clinical Evidence and Regulatory Approvals: The accumulation of clinical evidence supporting the efficacy and safety of radiopharmaceutical theranostics, along with regulatory approvals for new radiopharmaceuticals and indications, accelerates market adoption. Clinical trials demonstrate the benefits of theranostic approaches in improving patient outcomes, prolonging survival, and enhancing quality of life for cancer patients.

Recent Developments in the Radiopharmaceutical Theranostics Market:

Introduction of novel radiopharmaceuticals targeting specific biomarkers and molecular pathways implicated in cancer progression, metastasis, and treatment resistance, offering opportunities for personalized and targeted therapy in oncology.
Development and commercialization of companion diagnostic tests and imaging agents for patient selection, treatment response monitoring, and disease surveillance in theranostic applications, facilitating precision medicine approaches in clinical practice.
Integration of artificial intelligence (AI), machine learning (ML), and image analysis algorithms into radiopharmaceutical theranostics workflows to enhance diagnostic accuracy, treatment planning, and prognostic prediction in oncology and other disease areas.
Expansion of theranostic applications beyond oncology to include neurology, cardiology, endocrinology, and infectious diseases, driven by advances in molecular imaging, radiopharmaceutical chemistry, and disease-specific biomarkers.
Adoption of hybrid imaging platforms, advanced radiochemistry facilities, and cyclotron production capabilities in healthcare institutions and radiopharmaceutical manufacturing facilities to support theranostic research, production, and clinical translation.

Buy this Premium Research Report: - https://www.transparencymarketresearch.com/checkout.php?rep_id=82604<ype=S

Market Segmentation -

Segmentation

Radioisotope
Technetium-99
Gallium-68
Iodine-131
Radium-223
Fluorine-18
Yttrium-90
Lutetium-177
Copper-67 & 64
Samarium-153
Others

Application
Oncology
Cardiology
Others

Source
Nuclear Reactors
Cyclotrons

Approach
Targeted Therapeutic (Rx)
Companion Diagnostic (DX)

Radiotracer Type
Peptidic
Non-peptidic

End-user
Hospitals
Academic & Research Institutes
Others

This Report lets you identify the opportunities in Radiopharmaceutical Theranostics Market by means of a region:

North America (the United States, Canada, and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

Key Features of the Radiopharmaceutical Theranostics Market Report: -

➤ Analyze competitive developments such as expansions, deployments, new product launches, and market acquisitions.

➤ Examine the market opportunities for stakeholders by identifying higher growth sections.

➤ To study and analyze the global Radiopharmaceutical Theranostics industry status and forecast including key regions.

➤ An in-depth analysis of key product segments and application spectrum, providing strategic recommendations to incumbents and new entrants to give them a competitive advantage over others.

➤ It provides a comprehensive analysis of key regions of the industry as well as a SWOT analysis and Porter's Five Forces analysis to provide a deeper understanding of the market.

➤ It helps you make strategic business decisions and investment plans.

More Trending Reports by Transparency Market Research -

Plasma Fractionation Market: https://www.globenewswire.com/en/news-release/2024/03/06/2841356/32656/en/Plasma-Fractionation-Market-to-reach-USD-42-6-billion-by-2031-Expanding-at-a-CAGR-of-6-7-Transparency-Market-Research-Inc.html

Stretcher Chair Market: https://www.globenewswire.com/en/news-release/2024/03/06/2841462/32656/en/Stretcher-Chair-Market-Projected-to-Reach-USD-403-2-million-by-2031-Growing-at-a-CAGR-of-4-2-Transparency-Market-Research-Inc.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Radiopharmaceutical Theranostics Market Size is Expected to expand at a CAGR of 15.1% by 2031 |Transparency Market Research here

News-ID: 3435721 • Views:

More Releases from Transparency Market Research

Gas Compressor Market Outlook 2036: Global Industry Expected to Reach US$ 41.0 Billion by 2036 at 5.3% CAGR
Gas Compressor Market Outlook 2036: Global Industry Expected to Reach US$ 41.0 B …
The global gas compressor market was valued at US$ 23.2 Bn in 2025 and is projected to reach US$ 41.0 Bn by 2036, expanding at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2036. This steady growth trajectory reflects the structural importance of gas compression systems across upstream, midstream, and downstream gas value chains. Rising natural gas consumption, expansion of pipeline and LNG infrastructure, and national energy
Anesthesia Drugs Market to be Worth USD 12.6 Bn by 2036 - By Drug / By Application | U.S. • Germany • China • India
Anesthesia Drugs Market to be Worth USD 12.6 Bn by 2036 - By Drug / By Applicati …
The global anesthesia drugs market was valued at US$ 7.6 billion in 2025 and is projected to reach US$ 12.6 billion by 2036, expanding at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2036. This steady growth trajectory reflects the essential and non-substitutable role of anesthesia drugs in modern healthcare systems. As surgical interventions continue to rise globally-across both elective and emergency procedures-the demand for safe, effective,
Single-Atom Catalysts Market Size is Expected to Expand from US$ 177.8 Million to US$ 1,000.2 Million by 2036 at a 17.0% CAGR
Single-Atom Catalysts Market Size is Expected to Expand from US$ 177.8 Million t …
The global single-atom catalysts (SACs) market is poised for remarkable growth as industries seek highly efficient, cost-effective, and sustainable catalytic solutions. Valued at US$ 177.8 million in 2025, the market is projected to reach US$ 1,000.2 million by 2036, expanding at a robust compound annual growth rate (CAGR) of 17.0% from 2026 to 2036. This rapid expansion reflects the growing importance of advanced catalysis in energy, chemicals, environmental protection, and
Non-specific Endonuclease Market to Reach USD 726.6 Million by 2036, Supported by Biopharma Growth
Non-specific Endonuclease Market to Reach USD 726.6 Million by 2036, Supported b …
The non-specific endonuclease market is witnessing steady growth, driven by the expanding use of molecular biology tools across biotechnology, pharmaceuticals, diagnostics, and academic research. Non-specific endonucleases are enzymes that cleave nucleic acids without requiring a specific recognition sequence, making them highly valuable for applications such as DNA/RNA degradation, sample preparation, viscosity reduction, and contamination control. Their broad activity profile differentiates them from restriction enzymes and enables versatile usage across multiple

All 5 Releases


More Releases for Radiopharma

Nuclear Pharmacy Market Future Business Opportunities 2025-2032 | Curium Pharma, …
The Latest study titled Nuclear Pharmacy Market 2025, published by Coherent Market Insights, provides valuable insights into both regional and global markets projected to grow in value from 2025 to 2032. The comprehensive research delves into the evolving market dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. Additionally, the report
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and St …
Actinium's Chief Medical Officer, said, "In addition to demonstrating unprecedented 100% access to BMT in Iomab-B treated patients with active r/r AML and achieving the primary endpoint of dCR with high statistical significance, we are excited by the compelling outcomes in patients with a TP53 mutation in the SIERRA trial. We look forward to returning to EBMT and once again highlighting the positive results from the Phase 3 SIERRA trial
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma A …
Biotech Stocks Taking Centerstage As the pharmaceutical industry ventures deeper into the era of precision medicine, radiopharmaceuticals, particularly those involving alpha emitters like Actinium-225 (Ac-225), are gaining prominence for their targeted approach to cancer treatment. Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate
2030 Projections: Radiopharmaceutical Synthesizers Market to Deliver Dynamic Pro …
The Radiopharmaceutical Synthesizers Market Research Report 2023-2030 provides in-depth information on market trends, market capacity, industry size, growth factors, share, innovations, competitive environment, business problems, and more. This report's historical data confirms demand growth on a global, national, and regional scale. The studies on the global industry cover everything from comprehensive research to market size and forecasting to dynamics, growth factors, prospects, and hazards, as well as vendor knowledge. The
Automated Radiosynthesis Modules Market Strategic Assessment & SWOT Analysis 202 …
An Informative report titled as Global Automated Radiosynthesis Modules Market has recently been published by Report Consultant to its online repository. This statistical data offers an in-depth analysis by considering several segments, such as type, size, technology and applications. Different exploratory techniques such as, qualitative and quantitative analysis have been used to give data accurately. For better understanding of the customers, it uses effective graphical presentation techniques, such as graphs,
Cyclotron Market Growth Opportunities Analysis Report | GE Healthcare, Siemens H …
Cyclotron Market: Introduction According to the report, the global cyclotron market was valued at US$ 215.5 Mn in 2019. It is projected to expand at a CAGR of ~3% from 2020 to 2030. Expansion activities of key radiopharma players; applications in clinical trials; increase in the geriatric population; pipeline assessment of new drugs; and disease indication mortality are major factors driving the cyclotron market. The shutdown of a few nuclear reactors has led to the